Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | ABCB1 | P08183 | 7/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 2/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18106014 | 0.86 | CYP2C19 (0.62) | CYP2C19ABCB1NPSR1MEN1HTT | |
| SCHEMBL21892001 | 0.81 | ALDH1A1 (0.54) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL21892003 | 0.80 | CYP2C19 (0.65) | CYP2C19ABCB1NPSR1MEN1HTT | |
| SCHEMBL21470017 | 0.75 | HPGD (0.34) | — | |
| SCHEMBL22858362 | 0.73 | LMNA (0.52) | CYP2C19HTTKMT2ALMNA | |
| SCHEMBL16710294 | 0.72 | CYP2C19 (1.00) | CYP2C19ABCB1NPSR1MEN1HTT | |
| SCHEMBL28551481 | 0.72 | CYP2C19 (1.00) | CYP2C19ABCB1NPSR1MEN1HTT | |
| SCHEMBL4237838 | 0.72 | CYP2C19 (1.00) | CYP2C19ABCB1NPSR1MEN1HTT | |
| SCHEMBL8925834 | 0.72 | CYP2C19 (1.00) | CYP2C19ABCB1NPSR1MEN1HTT | |
| SCHEMBL11532025 | 0.68 | POLB (0.45) | CYP2C19ABCB1NPSR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10918687-B2 | Kava derived therapeutic compounds and methods of use thereof | KUALITY HERBCEUTICS LLC (US) | 2021-02-16 | — | — | US | disclosed |
| US-10624943-B2 | Kava derived therapeutic compounds and methods of use thereof | Kuality Herbceutics, LLC (US) | 2020-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10918687-B2 | Kava derived therapeutic compounds and methods of use thereof | KLK5, KLK4, KLK2 | CYP2C19 1201/4885ABCB1 1681/4885NPSR1 4640/4885 |
| US-10624943-B2 | Kava derived therapeutic compounds and methods of use thereof | KLK5, KLK4, KLK2 | CYP2C19 1201/4885ABCB1 1681/4885NPSR1 4640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.